These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28369441)

  • 1. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
    Birgy A; Delecourt M; Geslain G; Desselas E; Caseris M; Magnan M; Mariani-Kurkdjian P; Bidet P; Bonacorsi S
    J Antimicrob Chemother; 2017 Jul; 72(7):1911-1914. PubMed ID: 28369441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
    Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
    J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
    BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine.
    Thulin E; Thulin M; Andersson DI
    EBioMedicine; 2017 Sep; 23():111-118. PubMed ID: 28855073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 7. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
    Søraas A; Sundsfjord A; Jørgensen SB; Liestøl K; Jenum PA
    PLoS One; 2014; 9(1):e85889. PubMed ID: 24454943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Lactamases in amoxicillin-clavulanate-resistant Escherichia coli strains isolated from a Chinese tertiary hospital.
    Ding J; Ma X; Chen Z; Feng K
    Diagn Microbiol Infect Dis; 2013 Aug; 76(4):532-3. PubMed ID: 23726651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
    Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
    Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
    [No Abstract]   [Full Text] [Related]  

  • 10. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins.
    Wootton M; Walsh TR; Macfarlane L; Howe RA
    J Antimicrob Chemother; 2010 Jan; 65(1):79-81. PubMed ID: 19915068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases.
    Marre R; Schulz E
    Arzneimittelforschung; 1988 Jul; 38(7):863-5. PubMed ID: 3061383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
    Cohen Stuart J; Leverstein-Van Hall M; Kortmann W; Verlind J; Mulder F; Scharringa J; Fluit A; Ekkelenkamp M
    Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
    Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
    Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women.
    Duployez C; Loiez C; Cattoen C; Descamps D; Wallet F; Vachée A;
    Med Mal Infect; 2016 Dec; 46(8):436-441. PubMed ID: 27609597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Strain of Escherichia coli resistant to broad-spectrum cephalosporin and amoxicillin/clavulanic acid].
    Martín-Pozo A; Alós JI
    Rev Esp Quimioter; 2012 Sep; 25(3):222-3. PubMed ID: 22987271
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases.
    Sougakoff W; Jarlier V
    J Antimicrob Chemother; 2000 Sep; 46 Suppl 1():9-14; discussion 63-5. PubMed ID: 11051618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient.
    Nielsen KL; Hansen KH; Nielsen JB; Knudsen JD; Schønning K; Frimodt-Møller N; Hertz FB; Jansåker F
    Microbiologyopen; 2019 Dec; 8(12):e941. PubMed ID: 31573735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.